Program
zotemtegrast
Also written as “LY4268989” and “MORF-057”.
Its studies are mostly in Colitis, Ulcerative · Crohn Disease, led by Eli Lilly.
Furthest: phase 2, since Mar 10, 20228 company-led studies, 3 open or runningNext primary completion: May 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 83 open or running | phase 2since Mar 10, 2022 | Sep 16, 2020 | May 2027phase 2 · NCT07186101 |
- Named in Eli Lilly’s own pipeline as
Zotemtegrast
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 16, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04580745 · 67 enrolled · United States
- Mar 10, 2022Phase 2 study in Inflammatory Bowel DiseasesNCT05291689 · 39 enrolled · United States, Poland
- Oct 31, 2022Phase 2 study in Inflammatory Bowel DiseasesNCT05611671 · 280 enrolled · United States, Australia, Austria and more
- Jan 16, 2024Phase 2 study in Inflammatory Bowel DiseasesNCT06226883 · 385 planned · United States, Australia, Austria and more
- May 1, 2025Phase 1 study in HealthyNCT06964776 · 144 enrolled · United States
- Sep 16, 2025Phase 2 study in Colitis, UlcerativeNCT07186101 · 252 planned · United States, Austria, Brazil and more
- Feb 6, 2026Phase 2 study in Colitis, UlcerativeNCT07415044 · 1,431 planned · United States, Argentina, Brazil and more
- Jul 13, 2026Phase 1 study in HealthyNCT07707375 · 50 enrolled · United States
Ahead
- May 2027Primary completion: phase 2 study in Colitis, UlcerativeNCT07186101
- Sep 2028Primary completion: phase 2 study in Inflammatory Bowel DiseasesNCT06226883
- Jun 2030Primary completion: phase 2 study in Colitis, UlcerativeNCT07415044
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07707375Healthy · United States | 1 | Completed | Oct 8, 2026 | 50 |
| NCT07415044Colitis, Ulcerative · United States, Argentina, Brazil and more | 2 | Recruiting | Jun 2030 | 1,431 |
| NCT07186101Colitis, Ulcerative · United States, Austria, Brazil and more | 2 | Recruiting | May 2027 | 252 |
| NCT06964776Healthy · United States | 1 | Completed | Feb 17, 2026 | 144 |
| NCT06226883Inflammatory Bowel Diseases · United States, Australia, Austria and more | 2 | Recruiting | Sep 2028 | 385 |
| NCT05611671Inflammatory Bowel Diseases · United States, Australia, Austria and more | 2 | Completed | Nov 28, 2024 | 280 |
| NCT05291689Inflammatory Bowel Diseases · United States, Poland | 2 | Completed | Oct 18, 2023 | 39 |
| NCT04580745Healthy Volunteers · United States | 1 | Completed | Mar 31, 2021 | 67 |
How it is read
Names in the registry
- “LY4268989”, 4 entries
- “MORF-057”, 4 entries
Codes read as this program: MORF057.
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 4 studies
- Crohn Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.